Drug intelligence / Profile preview

duvie + sitagliptin

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Duvie + Januvia is a combination therapy for type 2 diabetes mellitus consisting of imeglimin (brand name Duvie) and sitagliptin (brand name Januvia). Imeglimin is an oral antidiabetic agent that acts by improving mitochondrial function and enhancing both insulin secretion and sensitivity. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby stimulating insulin release and decreasing glucagon secretion in a glucose-dependent manner. This combination targets multiple pathophysiological defects in type 2 diabetes to improve glycemic control.

Other names: duvie + januviaimeglimin + sitagliptin

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on duvie + sitagliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on duvie + sitagliptin.

Explore the full profile